Ashurst advised LGC, an international life sciences company (majority-owned by funds managed by private equity group Bridgepoint) on its acquisition of Dr Ehrenstorfer GmbH and the Laboratory Dr. Ehrenstorfer-Schafers.

Dr Ehrenstorfer is an internationally leading producer of pesticide and other organic reference materials with seat in Augsburg, Germany; it offers an extensive range of products including a number of very specialized materials, to the residue analysis and environmental testing market.

The Ashurst team was led by partner Dr Nikolaus von Jacobs and senior associate Dr Germar Enders (both corporate, Munich). The team comprised counsel Dr Christoph Rieken (commercial/IP, Munich), counsel Dr Maximilian Boemke (regulatory, Frankfurt), senior associate Dr Fabian von Samson-Himmelstjerna and associate Dr Angela Brücken (both corporate, Frankfurt).  Partner Dr Andreas Mauroschat and associate Laura Opree (both employment), partner Dr Klaus Herkenroth and associate Felix Krüger (both tax) and partner Peter Junghanel (real estate, all Frankfurt) also advised.